Finance

Lists
Why is BCAX down 2.79%?
Dive Deeper
BCAX:NASDAQ
Bicara Therapeutics Inc
$8.71
-2.79%
(-0.25) 1D
Nov 4, 11:56:38 AM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BCAX...
Open
$9.19
High
$9.28
Low
$8.71
Mkt. cap
576.37M
Avg. vol.
1.63M
Volume
216.41K
52-wk high
$30.99
52-wk low
$7.87
EPS
-$3.09
Shares outstanding
66.17M
No. of employees
103
Open
$9.19
High
$9.28
Low
$8.71
Mkt. cap
576.37M
Avg. vol.
1.63M
Volume
216.41K
52-wk high
$30.99
52-wk low
$7.87
EPS
-$3.09
Shares outstanding
66.17M
No. of employees
103
News stories
From web sources and news partners
About Bicara Therapeutics Inc
CEO-
Employees103
Founded2018
HeadquartersBoston, Massachusetts, United States
SectorBiotechnology
Industry-
Websitebicara.com
Analyst ratings
Based on 9 analysts giving stock ratings to BCAX in the past 3 months
Buy
Buy
7
Hold
1
Sell
1
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for BCAX in the last 3 months.
Highest
Current $8.71
$45.00 (+416.65%)
Average
$32.00 (+267.39%)
Lowest
$8.00 (-8.15%)
Analyst
Recommendation
Action
Price target
Projected
Date
David Lebowitz
BMO Capital
Buy
Reiterated
$35.00
+301.8%
11/04/2026
Richard Law CFA
Goldman Sachs
Sell
Downgraded
$8.00
-8.2%
10/29/2026
Stephen Willey
Stifel Nicolaus
Buy
Maintained
$45.00
+416.6%
10/29/2026
Tazeen Ahmad
Bank of America Securities
Buy
Maintained
$34.00
+290.4%
10/27/2026
Jeet Mukherjee
BTIG
Buy
Maintained
$39.00
+347.8%
10/26/2026
Unknown Analyst
Wedbush
Buy
Maintained
$33.00
+278.9%
10/26/2026
Boris Peaker
JonesTrading
Buy
Maintained
$30.00
+244.4%
10/25/2026
Judah Frommer
Morgan Stanley
Buy
Maintained
$41.00
+370.7%
10/20/2026
Unknown Analyst
BMO Capital
Buy
Initiated
$35.00
+301.8%
08/18/2026
Joseph Catanzaro
Mizuho Securities
Hold
Maintained
$20.00
+129.6%
08/13/2026
Rajan Sharma
Goldman Sachs
Hold
Reiterated
$20.00
+129.6%
08/11/2026
Eva Fortea Verdejo
Wells Fargo
Hold
Reiterated
$23.00
+164.1%
08/12/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$42.00
+382.2%
06/01/2026
Bradley Canino
Guggenheim
Buy
Maintained
$42.00
+382.2%
05/26/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/11/2026
Soumit Roy
JonesTrading
Buy
Maintained
$30.00
+244.4%
04/06/2026
Reni Benjamin
Citizens JMP
Buy
Initiated
$31.00
+255.9%
01/29/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
32.98M
32.99M
47.50M
45.77M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.70M
8.13M
12.74M
14.18M
Operating expense
40.68M
41.12M
60.24M
59.95M
Total operating expenses
40.68M
41.12M
60.24M
59.95M
Operating income
-40.68M
-41.12M
-60.24M
-59.95M
Other non operating income
-
-
-
-
EBT including unusual items
-36.29M
-37.33M
-56.16M
-55.38M
EBT excluding unusual items
-36.29M
-37.33M
-56.16M
-55.38M
Income tax expense
40.00K
53.00K
52.00K
61.00K
Effective tax rate
-0.11%
-0.14%
-0.09%
-0.11%
Other operating expenses
-
-
-
-
Net income
-36.33M
-37.39M
-56.21M
-55.44M
Net profit margin
-
-
-
-
Earnings per share
-0.67
-0.68
-0.93
-0.82
Interest and investment income
4.39M
3.79M
4.08M
4.58M
Interest expense
-
-
-
-
Net interest expenses
4.39M
3.79M
4.08M
4.58M
Depreciation and amortization charges
-
-
-
-
EBITDA
-40.65M
-41.08M
-60.20M
-59.91M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps